These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 15265243)

  • 1. The role of sevelamer in achieving the kidney disease outcomes quality initiative (K/DOQI) guidelines for hyperphosphatemia.
    Pai AB; Smeeding JE; Brook RA
    Curr Med Res Opin; 2004 Jul; 20(7):991-9. PubMed ID: 15265243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
    Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sevelamer. Comparison with calcium carbonate in the treatment of hyperphosphatemia in hemodialysis patients.
    Shaheen FA; Akeel NM; Badawi LS; Souqiyyeh MZ
    Saudi Med J; 2004 Jun; 25(6):785-91. PubMed ID: 15195212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
    Nagano N; Fukushima N
    Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM
    J Am Soc Nephrol; 2003 Sep; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
    Nolan CR; Qunibi WY
    Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
    Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
    Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N; Nagano N
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis.
    Nolan CR; Qunibi WY
    Kidney Int Suppl; 2005 Jun; (95):S13-20. PubMed ID: 15882308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
    Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
    J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis.
    Huybrechts KF; Caro JJ; Wilson DA; O'Brien JA
    Value Health; 2005; 8(5):549-61. PubMed ID: 16176493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
    Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
    Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S
    Clin Calcium; 2004 May; 14(5):771-7. PubMed ID: 15577041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis.
    Mason MA; Shepler BM
    Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Critical appraisal of sevelamer for the treatment of hyperphosphatemia in patients with chronic renal failure].
    Sesso R; Ferraz MB
    Rev Assoc Med Bras (1992); 2003; 49(1):103-8. PubMed ID: 12724821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
    Qunibi WY; Nolan CR
    Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.